Cabozantinib + TAS-102 for Colorectal Cancer

"Affirmative. According to clinicaltrials.gov, this medical research is currently recruiting patients who meet the requirements of the trial. It was initially posted on July 16th 2021 and most recently updated October 31st 2022 - with a goal of enrolling 12 subjects at one site."

"Cabozantinib's safety rating is assessed at 1 due to the fact that this trial only entered its initial phase, thus providing limited evidence of both efficacy and safety."

"Cabozantinib is frequently employed to treat individuals who have already had oxaliplatin chemotherapy. It can also be applied to high risk patients, those previously exposed to anti-VEGF medication, and renal cell carcinoma cases."

"This medical trial is enrolling 12 patients between 18 and 100 years of age who have been diagnosed with colorectal cancer. Additionally, they must be RAS wild-type (with the exception of those treated with panitumumab or cetuximab), experienced progression following a fluoropyrimidine, irinotecan, oxaliplatin treatment regime, possibly received prior Bevacizumab or Ramucirumab treatments, possess an Eastern Cooperative Oncology Group performance status less than 2 according to Appendix A guidelines and display a life expectancy greater than 3 months."

"Currently, there are 151 active clinical trials utilizing Cabozantinib, 15 of which are in Phase 3. Despite the majority being situated in Cordoba and Calabria, a total of 7375 sites have been established for this medication's testing."

"Affirmative, according to clinicaltrials.gov, this research endeavour is actively enrolling volunteers; the study was introduced on July 16th 2021 and recently updated on October 31st 2022. 12 individuals need to be registered from one medical facility for the trial's completion."

"Since 2012, Cabozantinib has been the subject of medical research with its earliest study sponsored by Exelixis. This first trial was successful enough to garner Phase 2 drug approval and now there are 151 active trials for this medication conducted in 48 countries across 1435 cities."

"This medical investigation is open to patients who are between 18 and 100 years old."

"The primary endpoint of this medical trial is the Dose Limiting Toxicity [DLT], which will be observed over a period of one year, beginning at the start date of treatment and ending four weeks after the last patient has started their own. Secondary outcomes include an evaluation of safety and tolerability using NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., overall survival rates among patients who received cabozantinib with TAS-102, as well as objective response rate (ORR) based on Response Evaluation Criteria In Solid Tumors Version 1.1 (REC"